<DOC>
	<DOCNO>NCT00027144</DOCNO>
	<brief_summary>Description : The trial design determine response immune system patient CML vaccine make tumor . Researchers believe particular vaccine , make purify heat shock proteins take patient 's tumor , alert body 's immune system recognize attack invade cancer . To consider potentially eligible study must CML chronic phase . Length/Duration : Vaccinations administer weekly eight week . One clinic follow visit schedule two week final vaccination .</brief_summary>
	<brief_title>Study Using Vaccination With Heat Shock Protein 70 ( HSP70 ) Treatment CML Chronic Phase</brief_title>
	<detailed_description>Rational immunotherapy CML Conceptually , CML chronic phase best model immunological intervention . It disease result chromosomal translocation , generate true tumor-specific antigen . Patients chronic phase relatively preserve immune function prolong period time . Studies indeed show peptide span junctional region bcr/abl abl/bcr fusion proteins bind major histocompatibility complex ( MHC ) class I molecules ( Berke et al . 2000 ) . Vaccination patient bcr/abl breakpoint fusion peptide generate specific immune response ( Pinilla-Ibarz et al . 2000 ) . In addition , patient relapse bone marrow stem cell transplant , donor lymphocyte infusion effective inducing majority remission . The role donor lymphocyte infusion prove original concept graft versus leukemia effect effectiveness immunotherapy , practice , towards CML ( Dazzi et al . 1999 ) . More recently , find presence cytotoxic T lymphocytes ( CTL ) HLA-A2-restricted myeloid-specific antigen proteinase 3 correlate significantly cytogenetic remission CML treat either IFN stem cell transplant ( Molldrem et al . 2000 ) , provide strong evidence role T cell immunity clear malignant cell . Current proposal hypothesis : Based establish role HSPs T cell immunity large body preclinical clinical safety data , propose initiate pilot study test feasibility immunization autologous tumor-derived HSP70 treatment CML chronic phase . This study facilitate clinical trial future , test ultimate hypothesis combination cytostatic therapy IFN STI571 , specific immunomodulator HSP70 offer best chance eradication CML . A total 10 eligible patient enrol study . All eligible patient undergo aphaeresis collect peripheral blood mononuclear cell . The autologous HSP70 purify use standard protocol . After pass establish sterility testing , patient immunize intradermally 50 microgram HSP70 total 8 injection 2 month . They may receive standard therapy time . In addition collect feasibility toxicity data , development anti-tumor immunity measure , 1. increase peripheral blood IFN-gamma produce CD8+ T-lymphocytes reactive autologous bcr/abl positive peripheral mononuclear cell 2. increase PR-1 specific CTLs PR1-HLA-A2 tetramer technique patient HLA-A2 positive 3. change immunophenotype peripheral lymphocytes 4. cytogenetic remission Philadelphia chromosome bone marrow</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>ELIGIBILITY Inclusion : ECOG Performance Score ( PS ) less 2 . Must least 18 year age capable give informed consent . Must le three year original diagnosis Philadelphia chromosome positive CML chronic phase . Patient cytogenetic remission . No anticipation bone marrow stem cell transplant six month unless therapy deem necessary treatment physician due evolution disease ; Concurrent treatment hydroxyurea Gleevec allowed.PAST treatment IFN alpha , AraC cytoxic agent allow Must serious illness medical condition might compromise participation study . Must adequate renal function ( serum creatinine &lt; 2.0 ) , hepatic function ( bilirubin transaminase le 2.0 x upper normal limit ) . Must corticosteroid therapy , immunosuppressive medication . Exclusion Patients ECOG Performance Score great equal 2 . Patient great equal 3 year original diagnosis . Significant anemia ( Hemoglobin &lt; 10 g/dl ) thrombocytopenia ( platelet &lt; 20,000/ml ) require transfusion . Peripheral blast count 10 % . Positive urine blood pregnancy test . Impaired renal function ( serum creatinine &gt; 2.0 ) , hepatic function ( bilirubin transaminase 2.0 x upper normal limit ) . Patient significant active infection require hospitalization time enrollment . Patient significant behavioral psychological problem prevent adequate followup . Concurrent treatment IFN alpha AraC cytotoxic agent ( Gleevec hydroxyurea allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Vaccine</keyword>
</DOC>